Upfront ALK and VEGFR inhibition re-sensitized ALK-TKI-resistant ALK-positive NSCLC cell lines. Lorlatinib plus bevacizumab achieved disease regression. This evidence concerns the gene ALK and non-small cell lung carcinoma.